×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NYSE:CANF

Can-Fite BioPharma Stock Forecast, Price & News

$0.90
-0.02 (-2.17%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.86
$0.93
50-Day Range
$0.83
$1.02
52-Week Range
$0.78
$2.60
Volume
214,455 shs
Average Volume
389,261 shs
Market Capitalization
$24.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Can-Fite BioPharma Stock Forecast (MarketRank)

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Can-Fite BioPharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.42) to ($0.17) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.35 out of 5 stars

Medical Sector

1385th out of 1,429 stocks

Pharmaceutical Preparations Industry

666th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive CANF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Can-Fite BioPharma logo

About Can-Fite BioPharma (NYSE:CANF)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

CANF Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
8
Year Founded
N/A

Company Calendar

Last Earnings
5/26/2022
Today
7/01/2022
Fiscal Year End
12/31/2022

Profitability

Net Income
$-12.61 million
Net Margins
-1,447.36%
Pretax Margin
-1,478.90%

Debt

Sales & Book Value

Annual Sales
$850 thousand
Book Value
$0.53 per share

Miscellaneous

Free Float
N/A
Market Cap
$24.47 million
Optionable
Not Optionable
Beta
1.86














Can-Fite BioPharma Frequently Asked Questions

How has Can-Fite BioPharma's stock performed in 2022?

Can-Fite BioPharma's stock was trading at $1.20 at the beginning of the year. Since then, CANF stock has decreased by 25.0% and is now trading at $0.90.
View the best growth stocks for 2022 here
.

How were Can-Fite BioPharma's earnings last quarter?

Can-Fite BioPharma Ltd. (NYSE:CANF) posted its quarterly earnings data on Thursday, May, 26th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.03. The business earned $0.21 million during the quarter, compared to analyst estimates of $0.20 million. Can-Fite BioPharma had a negative net margin of 1,447.36% and a negative trailing twelve-month return on equity of 132.72%.
View Can-Fite BioPharma's earnings history
.

Who are Can-Fite BioPharma's key executives?

Can-Fite BioPharma's management team includes the following people:
  • Dr. Pnina Fishman Ph.D., Scientific Founder, CEO & Director (Age 74, Pay $644k)
  • Mr. Motti Farbstein, Chief Operating & Financial Officer (Age 58, Pay $416k)
  • Dr. Sari Fishman Ph.D., VP of Bus. Devel. (Age 50, Pay $317k)
  • Dr. Ilan Cohn Ph.D., Co-Founder & Chairman (Age 68)
  • Dr. Vibeke Strand FACP, FACR, FACR (USA), M.D., Sr. Clinical Advisor

What is Can-Fite BioPharma's stock symbol?

Can-Fite BioPharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "CANF."

How do I buy shares of Can-Fite BioPharma?

Shares of CANF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Can-Fite BioPharma's stock price today?

One share of CANF stock can currently be purchased for approximately $0.90.

How much money does Can-Fite BioPharma make?

Can-Fite BioPharma (NYSE:CANF) has a market capitalization of $24.47 million and generates $850 thousand in revenue each year. The company earns $-12.61 million in net income (profit) each year or ($0.66) on an earnings per share basis.

How many employees does Can-Fite BioPharma have?

Can-Fite BioPharma employs 8 workers across the globe.

How can I contact Can-Fite BioPharma?

Can-Fite BioPharma's mailing address is 10 BAREKET STREET KIRYAT MATALON P.O. BOX 7537, PETACH TIKVA L3, 4951778. The official website for Can-Fite BioPharma is www.canfite.com. The company can be reached via phone at 972 3 924 1114, via email at [email protected], or via fax at 972-3924-9378.

This page (NYSE:CANF) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.